ReproCell Stock

ReproCell Tangible Book Value per Share

The Tangible Book Value per Share of ReproCell (4978.T) as of Sep 4, 2026 is 96.48 JPY. In the previous year, Tangible Book Value per Share was 89.25 JPY — a change of 8.09% (higher).

Tangible Book Value per Share

96.48JPY

YoY

8.09%

Last updated:

Tangible Book Value per Share of ReproCell is 2026 96.48 JPY. Tangible Book Value per Share of ReproCell was 2025 89.25 JPY. It decreases by 8.09% higher compared to the previous year.

The ReproCell Tangible Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Tangible Book Value per Share
Date
Tangible Book Value per Share
Jan 1, 2018
67.28 JPY
Jan 1, 2019
74.93 JPY
Jan 1, 2020
64.70 JPY
Jan 1, 2021
57.59 JPY
Jan 1, 2022
77.78 JPY
Jan 1, 2023
81.42 JPY
Jan 1, 2024
89.25 JPY
Jan 1, 2025
96.48 JPY
The ReproCell Tangible Book Value per Share history
YEARTangible Book Value per ShareYoY
96.48JPY+8.09%
89.25JPY+9.62%
81.42JPY+4.69%
77.78JPY+35.04%
57.59JPY-10.99%
64.70JPY-13.65%
74.93JPY+11.37%
67.28JPY+5.89%
63.53JPY+10.00%
57.76JPY+7.75%
53.60JPY-4.15%
55.92JPY+773.11%
6.40JPY+2.98%
6.22JPY-8.88%
6.83JPY-12.55%
7.80JPY-3.49%
8.09JPY+86.38%
4.34JPY
Access this data via the Eulerpool API

ReproCell Stock analysis

What does ReproCell do? ReproCell, Inc. is a company that was founded in 2003 and specializes in the research and manufacture of cell cultures. The company is based in Yokohama, Japan and operates worldwide. Its business model includes providing services and products to support research and development activities in the field of regenerative medicine and cell therapy. The company is divided into three main divisions: the Biorepository Division, which provides human cells and tissues for research purposes; the Cell Manufacturing Division, which develops production processes for cell therapy products; and the Drug Discovery Division, which supports drug development through screening and in vitro testing. ReproCell offers a variety of cell cultures, including stem cells from various sources, as well as related media, reagents, and tools for cultivation and application. In addition, the company offers services in cell therapy production, working closely with customers to provide customized and high-quality therapies. ReproCell also supports drug and compound research through screening and in vitro testing, with various platforms available for the identification and evaluation of new compounds. The company has a history of growth and has become a leading player in the field of cell culture and cell therapy production. In conclusion, ReproCell plays a significant role in regenerative medicine and cell therapy production, offering a wide range of products and services to support research and development in these areas. It is poised to continue its growth and contribute to the development of new therapies in the future. ReproCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ReproCell stock

Tangible Book Value per Share of ReproCell is 96.48 JPY in 2026.

Tangible Book Value per Share of ReproCell changed from 89.25 JPY to 96.48 JPY, representing a 8.09% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Tangible Book Value per Share ReproCell since 2006 – with annual values, charts, and detailed analysis.

Tangible book value per share excludes intangible assets and goodwill, providing a more conservative measure of per-share net asset value.

Access this data via the Eulerpool API

Balance Sheet — ReproCell

All Key Metrics — ReproCell